The response includes a considered implementation plan to strengthen the regulation of medical devices and in vitro diagnostics, improve patient safety, and foster innovation post-Brexit.

On 26 June 2022, the UK Medicines and Healthcare products Regulatory Agency (MHRA) published its long-awaited response to its consultation on the UK’s post-Brexit regulatory regime for medical devices and in vitro diagnostic (IVD) medical devices. The 10-week public consultation concluded in November 2021. The response factors in feedback and observations from almost 900 respondents, including views from industry, the wider healthcare sector, and patients.